IP Library Patent Application 13765531
Patent Application
App. No. 13/765,531

METHOD FOR THE PURIFICATION OF RECOMBINANT BLOOD COAGULATION FACTOR IX ENRICHED IN SULFATED AND/OR PHOSPHORYLATED MOLECULES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/765,531
Abstract

The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer having a salt concentration of more than 200 mM. The purification according to the invention provides a method to enrich rFIX molecules which have been posttranslationally modified by sulfation and/or phosphorylation. The present invention further relates to purified rFIX compositions enriched in monosulfated and/or monophosphorylated rFIX molecules.

Claims (25)

1 - 7 . (canceled)

8 . A purified composition comprising rFIX obtained by a method, the method for obtaining the composition comprising the steps:

a) loading a starting composition comprising rFIX onto an anion exchange column.,

b) washing the anion exchange material using a wash buffer which has a salt concentration of more than 200 mM (High Salt Wash Buffer), and

c) eluting the rFIX from the anion exchange material using an elution buffer comprising divalent cations, and

d) collecting the eluate.

9 . The purified composition according to claim 8 , wherein said purified composition comprises an increased relative amount of monosulfated and/or monophosphorylated rFIX molecules compared to the relative amount of monosulfated and/or monophosphorylated rFIX present in the High Salt Wash Buffer fraction.

10 . The purified composition according to claim 8 , wherein said purified composition comprises a relative amount of monosulfated and monophosphorylated rFIX molecules which is increased at least 3 fold compared to the relative amount of monosulfated and monophosphorylated rFIX present in the High Salt Wash Buffer fraction.

11 . The purified composition according to claim 8 , wherein said purified composition comprises a relative amount of at least 30% of monosulfated and/or monophosphorylated rFIX molecules.

12 . The purified composition according to claim 8 , wherein said purified composition comprises a relative amount of at least 50% of monosulfated and monophosphorylated rFIX molecules.

13 . The purified composition according to claim 8 , wherein the rFIX is human rFIX.

14 . The purified composition according to claim 8 , wherein the wash buffer has a conductivity of at least 21 mS/cm at 25° C.

15 . The purified composition according to claim 8 , wherein the wash buffer wherein the wash buffer has a conductivity of 21±1 mS/cm at 25° C.

16 . The purified composition according to claim 8 , wherein the elution buffer has a higher conductivity than the starting composition comprising rFIX.

17 . The purified composition according to claim 8 , wherein the elution buffer has a lower conductivity than the wash buffer which has a salt concentration of more than 200 mM, and which has a higher conductivity than the composition comprising rFIX.

18 . The purified composition according to claim 8 , wherein the elution buffer has a conductivity of at least 10 mS/cm at 25° C.

19 . The purified composition according to claim 8 , wherein the elution is conducted with a gradient of elution buffers having different salt concentrations.

20 . The purified composition according to claim 8 , wherein eluting the rFIX from the anion exchange material includes using a gradient of anions in an elution buffer comprising divalent cations.

21 . The purified composition according to claim 8 , wherein the concentration of divalent cations in the elution buffer is from 0.5 mM to 10 mM.

22 . The purified composition according to claim 8 , wherein the concentration of divalent cation in the elution buffer is from 2 mM to 5 mM.

23 . The purified composition according to claim 8 , wherein the concentration of divalent cation in the elution buffer is 2 mM.

24 . The purified composition according to claim 8 , wherein the divalent cation in the elution buffer is Ca 2+ .

25 . The purified composition according to claim 8 , wherein the elution buffer has a pH of from 6 to 9.

26 . The purified composition according to claim 8 , wherein the elution buffer has a pH of from 7 to 8.

27 . The purified composition according to claim 8 , wherein the elution buffer has a pH of 7.4±0.2.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036362/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036374/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2014
From: MITTERER, ARTUR; HASSLACHER, MEINHARD; FIEDLER, CHRISTIAN
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 033557/0223 →